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Abstract
Recently discovered macrocyclic carbon suboxide (MCS) factors with the general formula (C3O2)n were found to strongly inhibit rabbit
and rat Na,K-ATPase as well as SR Ca-ATPase. Highly active MCS factors were obtained by a base/acid treatment of their lipophilic
precursor isolated from plants. In the ESI-MS spectra, the dominant molar mass ion of 431 Da corresponds to a 1:1 complex of the carbon
suboxide hexamer (n= 6; Mr = 408 Da) with a Na
+ ion. Additional mass ions identified in positive and negative ion mode were assigned as
complexes of the MCS hexamer (n = 6) and octamer (n = 8) with Na+ or with TFA in various ratios. The dominant mass ion values of these
active MCS factors from plants are also found in mass spectra of previously described endogenous digitalis-like factors (EDLF) from
animals. This would suggest that ubiquitously distributed MCS factors may function as putative endogenous regulatory substances of Na,K-
ATPase and possibly of other ATPases. With the symmetric display of several equivalent carbonyl or hydroxy groups, the structure of MCS
factors is particularly suited for interactions with proteins and other bio-molecules. This could explain the high biological activity and the
unusual properties of the MCS factors.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
The Na,K-ATPase (EC 3.6.1.37) or sodium pump is a
plasma membrane protein ubiquitously present in all higher
eucaryotic cells. It belongs to the larger family of P-type
ATPases with the common feature of forming a phosphory-
lated intermediate during the pump cycle. Sodium pumps
control a broad spectrum of essential cellular functions such
as ionic homeostasis, membrane potential, pH, temperature,
water osmosis [1], thereby regulating different physiological
processes, e.g. muscle contraction, nervous signal trans-
mission, renal sodium retention, vascular tone, etc. [2]. This
multiple regulatory potential of the same enzyme is ex-
plained by the existence of tissue-specific assemblies of
different structural subunits or isoforms [3]. The physiolog-
ical role of the various isoforms may consist of different
sensitivities towards endogenous regulators of the pump [4].
Malfunctions of the Na,K-ATPase are clearly involved in
several pathologies such as essential hypertension, cardiac
failure, diabetes and others [5,6]. It is therefore of major
therapeutic interest to elucidate the physiological regulatory
mechanism of the Na,K-ATPase which is—despite all
efforts—still not well understood.
Calcium homeostasis inside the eucaryotic cells is main-
tained by the ubiquitously distributed membrane enzymes
known as Ca-ATPases or Ca pumps. The plasma membrane
Ca-ATPase generally counteracts the influx of free Ca2 +
ions through calcium channels and thus exerts an essential
role in controlling enzymatic reactions and a broad spectrum
of intracellular signaling processes [7]. In muscle cells, the
SR Ca-ATPase pumps Ca2 + ions back into the sarcoplasmic
reticulum stores during muscle relaxation. Ca-ATPase is
structurally related to the Na,K-ATPase [8], both belonging
to the super-family of P-type ATPases evolved presumably
from a common archaic ancestor 3.5 billion years ago [9].
Extensive studies performed in the past support the
presence in animal tissues and fluids of some endogenous
inhibitors of the sodium pump (called endogenous digitalis-
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like factors, EDLFs) [10–12]. However, their chemical
nature remained elusive, and digitalis steroids and partic-
ularly ouabain are still discussed as the putative endogenous
ligand candidates [13,14]. It is, however, rather improbable
that digitalis steroids exert this general function, since they
are: highly toxic for animals, biosynthesized only by a few
rare plants and toads, inactive towards some Na,K-ATPase
isoforms, and generally towards Ca-ATPase and other P-
type ATPases. So far, all evidences confirm the original
statement of Szent-Gyo¨rgyi [15] that cardiac steroids are
only some substitutes of the actual endogenous regulatory
factors and nothing more.
Recently, a new class of natural products defined as
macrocyclic carbon suboxide (MCS) factors with the gen-
eral formula (C3O2)n was identified as potent sodium pump
inhibitors [16,17]. The proposed structure of these MCS
factors corresponds to head-to-tail condensed pyran-4-one
rings additionally joined in a cylindrical macrocycle as
shown in Fig. 1 for n = 6 and n = 8.
The repeating unit of this macrocyclic structural frame is
carbon suboxide OMCMCMCMO, the known homologue of
CO and CO2 [18]. Thus, the macrocyclic compounds
reported in Fig. 1 are actually the cyclohexamer (C3O2)6
and cyclooctamer (C3O2)8 of the inorganic carbon suboxide:
C3O2. This structural assumption is in full agreement with
the experimentally determined molar masses of 408.2 and
544.2 Da for the cyclohexamer (C3O2)6 and cyclooctamer
(C3O2)8, respectively. These cyclo-oligomers of the carbon
suboxide may be classified both as inorganic and organic
substances.
Carbon suboxide may be generated from carbon mon-
oxide by simple electric discharges; thus the presence of
C3O2 in the archaic earth atmosphere, rich in CO, is very
probable. In this sense, MCS factors could be present in the
earlier phase of the evolution when the ancestor P-type
ATPases evolved [9,17].
The MCS factors were isolated from herbal sources in the
form of a structurally less defined lipophilic precursor [16].
In the present communication, a simple and convenient
method is described to convert this lipophilic MCS precur-
sor into a hydrophilic form with significantly enhanced
inhibitory potency. HPLC and mass spectrometry of the
active MCS factors served to characterize these active
forms. Their inhibitory activity on the sodium pump from
rabbit and rat was compared to that of ouabain. The
similarly potent inhibition of SR Ca-ATPase by the MCS
factors is additionally reported.
2. Materials and methods
Phosphoenolpyruvate (PEP), pyruvate kinase, lactate
dehydrogenase, NADH and ATP (disodium salt) were from
Boehringer (Mannheim). All other reagents were purchased
from Merck (Darmstadt) or Sigma-Aldrich (Deisenhofen) at
the highest quality available.
Analytical HPLC was carried out on Kontron-Instru-
ments device using a 250/4 mm Nucleosil RP 100-5 column
(Macherey-Nagel, Du¨ren, Germany) with a linear gradient
of 5–95% acetonitrile in water (both containing 0.05%
TFA) for 45 min and at a flow rate of 1.0 ml/min and
detection with DAD-440. For LC-MS the microgradient
system type 140c (Perkin-Elmer) coupled to PE SCIEX API
165 ESI detector was used with a Nucleosil 2/100 column
and a linear gradient of 5–95% acetonitrile in water (0.05%
TFA) in 20 min. The ESI mass spectra were recorded in
both the positive and negative ion mode.
2.1. Isolation of the lipophilic MCS precursor
Hexane-defatted roots (1.0 kg) of Helleborus purpuras-
cens were stirred for 24 h at 20 jC in 70% EtOH (8.0 l), and
the resulting solution was concentrated under reduced
pressure to a volume of 1.5 l. The aqueous emulsion was
then extracted twice with a mixture of hexane (1.2 l)/
chloroform (0.3 l), the aqueous phase was separated and
acidified to pH 1.5 and extracted twice with tert-butyl
methyl ether (1.2 l). The organic phase was washed to
neutral pH with 0.2 M NaCl, dried over Na2SO4 and
evaporated to dryness. The resulting brownish, crude lip-
ophilic product (yield: 1.8–3.5 g) was purified roughly by
solving it in acetone (50 mg/ml) and mixing the acetone
solution with 10-fold volume of n-hexane. The vacuum-
dried precipitate was further purified by semi-preparative
HPLC on a SP 250/10 mm Nucleosil 100-5 C-18 HD
column (Macherey-Nagel) at a flow rate of 3.0 ml/min with
a linear gradient of 5–90% acetonitrile/water (both contain-
ing 0.1% TFA) for 45 min. This chromatographic purifica-
tion was repeated three to five times until the broad
symmetrical HPLC peak of the lipophilic product was free
of any impurity detectable spectroscopically in HPLC (at
205 nm) and of organic impurities detectable by TLC (silica
plates, Merck) by visualizing with the anisaldehyde/sulfuric
acid reagent. The absence, even in trace amounts, of so far
isolated organic compounds from Helleborus species ex-
tracts, e.g. steroid glycosides, saponines, ecdysones, lac-
tones, etc., was verified separately by mass spectrometry.
Final yield of the highly purified lipophilic precursor: 27–
32 mg calculated for 1 kg dried Helleborus roots.Fig. 1. Structure of the MCS hexamer and octamer.
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2.2. Preparation of the active MCS factors
The purified and lyophilized lipophilic precursor (1 mg)
was dissolved in 1 ml 50% EtOH, diluted with 1.2 M NaOH
(5 ml) to a final concentration of 0.167 mg/ml. The alkaline
solution was boiled in a round-bottom flask equipped with a
water-cooled condenser for 12 h under slow stirring in an oil
bath (116 jC). The optimal boiling time for activation of the
lipophilic component was found to be 8–14 h (vide infra).
After boiling, the alkaline MCS solution was adjusted with
1 M HCl first to a pH value of 8.0–9.6 and then to a final
pH of 3 or less. To remove the excess Na+ ions after boiling
in NaOH, the acidified solution was treated with a strong
cation-exchanger resin, e.g. for 150 Al MCS-402 solution
(pH 3) 40 mg of Amberlyst 15 were used resulting the
probe: MCS-L04. The activity of the Na-free MCS solutions
is well preserved by storage at + 4 jC for 6 months and
longer. Several details in the preparation of the highly active
MCS factors are apparently of decisive importance,
although not fully understood. Thus, a too rapid acidifica-
tion of the boiled alkaline probe from pH >13 to acidic pH
values can lead to a gel-like inactive substance. Titration
with diluted HCl (less than 1 M) produced very potent
inhibitors, but their activity decayed within a few days’
storage at room temperature.
2.3. Enzyme assays
Membrane preparations with a high concentration of
Na,K-ATPase (about 5000 pumps per Am2) were prepared
from the outer medulla of rabbit and rat kidneys using
procedure C of Jørgensen [19]. The specific ATPase activity
was in the range of 2000–2400 Amol Pi/h/mg protein at 37
jC for the rabbit enzyme and 2000 Amol Pi/h/mg protein for
the rat enzyme. The enzyme activity of the Na,K-ATPase
[22] was determined in a buffer containing 25 mM imida-
zole (pH 7.2), 100 mM NaCl, 10 mM KCl, 5 mM MgCl2,
1.5 mM Na2ATP, 5 nM Na,K-ATPase, 2 mM PEP, 450
units/ml of pyruvate kinase and lactate dehydrogenase, and
initially 80 AM NADH. All experiments were performed at
37 jC. The enzyme activity in absence of inhibitor was used
as reference. Molar concentration of the MCS solutions was
calculated on the basis of a Mr of 408.2 Da because the
actual ratio between MCS cyclohexamer and cyclooctamer
could not be established precisely. Using the lower Mr
instead of the 544.2 Da for the octamer resulted in a more
conservative estimate with possibly higher molar concen-
tration of the inhibitor and, therefore, lower values of the
specific activity. The pyruvate kinase/lactate dehydrogenase
assay was not affected by MCS. The inhibitory action of the
MCS compounds was fully developed within the time of
mixing the buffer in the cuvette with the inhibitor solution
added (1–10 Al). In the presence of excess ouabain, the
Na,K-ATPase preparation was fully inhibited, a fact which
confirmed the high degree of purity of the enzyme prepa-
ration as additionally controlled by SDS electrophoresis
(data not shown). The normalized specific activity was
calculated as the ratio of the residual activity upon addition
of increasing amounts of MCS, and the reference activity.
Ca-ATPase was prepared from rabbit psoas muscle by a
slight modification of the method of Heilmann et al. [20].
The whole procedure was performed at temperatures below
4 jC. The protein content of the membrane preparation was
determined as described previously [21] and was found to
be 2–3 mg/ml for the most active fractions after the final
density gradient separation. The specific enzymatic activity
was about 2 Amol Pi/h/mg protein at 20 jC. The enzyme
activity was determined by the same coupled pyruvate
kinase/lactate dehydrogenase assay as in the case of the
Na,K-ATPase using buffer (pH 7.5) containing 25 mM
HEPES, 1 mM MgCl2, 50 mM KCl, and 0.2 mM Ca
2 +.
Background enzyme activity of the isolated preparation was
obtained by addition of 1 AM tharpsigargin. The specific
activity of the Ca-ATPase preparation was f 1.8 units/mg
at 20 jC and pH 7.5 (which corresponds to 1.8 Amol ATP
hydrolyzed per mg protein per min).
3. Results and discussion
3.1. HPLC characterization of the MCS factors
In the analytical HPLC analysis the purified lipophilic
precursor elutes as a broad symmetric peak at tR = 24.6 min
which corresponds to f 54% acetonitrile concentration
(Fig. 2). Standard cardiac glycosides elute under identical
conditions at tR = 13.3 min (ouabain), 19.1 min (hellebrin)
and 22.2 min (digoxin). The pure active MCS factors
resulting from the base/acid treatment elute shortly after
the injection peak as shown in a HPLC diagram of a mixture
of the active substance with its lipophilic precursor (Fig. 2).
However, MCS factors show a pronounced tendency to co-
elute with other substances. This was proved by HPLC-MS
runs with selected mass ion (SMI) detection, i.e. of 409, 431
or 521 Da (vide infra).
Broad HPLC elution is explained by the existence of
self-associations between variously structured MCS factors,
especially through semi-acetal bonds between carbonyl and
hydroxy groups. HPLC co-elution with other substances are
similarly assigned to possibly strong associations between
MCS factors and carbohydrates, peptides and similar sub-
stances. Both kind of associations are particularly enhanced
by the symmetric display of several equivalent carbonyl or
hydroxy groups in the structure of the MCS factors (Figs. 1
and 5).
3.2. Mass spectrometric analysis of the MCS factors
In Fig. 3, the ESI-MS spectrum of the highly active
preparation: MCS-L04 recorded in the positive-ion mode is
reported. The principal mass ion peaks (m/z) correspond to
complexes between the MCS hexamer (C3O2)6 or octamer
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(C3O2)8 and Na
+. The mass ion peak at 431.2 Da was
therefore assigned to a 1:1 complex of the MCS hexamer
with Na+, while the peaks with m/z = 295.2 and 159.0 Da
correspond to the [2(C3O2)6 + 3Na
+] and [(C3O2)6 + 3Na
+]
complexes. These multiple-charge mass ion complexes are
generated presumably in the ionization chamber from the
more stable 1:1 complex in a mode similar to that reported
for the crown–ether complexes with alkali ions [23]. The
positive mass ion peak at 567.2 Da was assigned to a 1:1
complex of the 544 Da octamer (C3O2)8 with Na
+. Assum-
ing the existence of multiple charged mass ions, the m/
z = 295.2 Da (see above) may also be assigned to the
complex [(C3O2)8 + 2Na
+], while the m/z = 159 Da peak
may be the [(C3O2)8 + 4Na
+] complex. In the positive mode
spectrum additional mass ion peaks of weak intensity were
detected at 353.0, 489.0, and 624.8 Da which should
correspond to complexes between one Na+ ion and MCS
forms with n = 5, 7 and 9. Since the MCS oligomers as odd
multiples of carbon suboxide are less probable, these may
be generated in situ in the ionization chamber.
Interestingly, the principal mass ion values of the MCS
factors in the positive ion mode can also be found in the
mass spectra of EDLF isolated from animal tissues and
fluids. In the FAB-MS spectrum of the EDLF isolated from
human plasma [24], the 409 Da peak was considered as the
molar mass ion, but without any structural proposal. The
further mass ion peaks present at 431 and at 447 Da were
assigned as adducts of Na+ and K+ to the molecule of
unknown structure, whereas the mass peak of 839 Da was
attributed to a dimer complexed with a Na+ ion. Further
Fig. 3. ESI mass spectrum of the MCS-L04 factor in the positive ion mode.
Fig. 2. HPLC elution of the lipophilic precursor and of the highly active hydrophilic MCS factor prepared by the base/acid treatment, compared with standard
cardiac steroids.
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mass peaks observed at 545 and 567 Da were not assigned
[24], but can now be attributed to the MCS octamer with a
Na+ ion. For EDLF from human placenta, a 409 Da molar
mass ion was reported [25], and the same mass ion is
present in the MS spectrum of the EDLF from human
plasma [26]. The molar mass ion of 625 Da for the EDLF
factor isolated from pig urine which could not be assigned
[27] may well correspond to the 624.8 Da peak of Fig. 4.
The ESI-MS spectrum of the MCS factors recorded in
negative mode is shown in Fig. 4. The mass ion peaks (m/z)
correspond to the negatively charged complexes of the MCS
hexamer or of the octamer complexed with the trifluorace-
tate anion in various ratios. Thus, the 249.0 Da peak
corresponds to [(C3O2)6 + 3CF3COO
]/3, the 384.8 Da peak
to [2(C3O2)6 + 3CF3COO
] the 521.0 Da peak to the
[(C3O2)6 + CF3COO
] and the 656.8 Da peak to the
[(C3O2)8 + CF3COO
] mass ion.
From a first quantitative analysis of the peak intensities a
ratio of 65:35 was determined between the cyclohexamer/
octamer forms of the MCS factors in the ESI-MS spectra.
The intensity of the 295.2 and 159.0 Da mass ion peaks are
less significant because they are assumed as multiple
charged ions which may result both from cyclohexamer
and -octamer. Due to the complex processes in the ioniza-
tion chamber the preliminary composition data will be
investigated in further studies.
3.3. Inhibitory potencies of the MCS factors
The lipophilic precursor is assumed to be a randomly
structured polycarbonylic product that probably is produced
by polyketide-synthase enzymes of ubiquitous distribution.
Malonyl-coenzyme-A is known as building block of poly-
ketides and carbon suboxide is actually the bis-anhydride of
malonic acid. The purified lipophilic precursor inhibits the
Na,K-ATPase with an IC50 of 0.5–2.5 Ag/ml, while upon
activation a significantly enhanced potency (IC50 = 0.015
Ag/ml) was observed. By the alkaline treatment of the
polyketide precursor it is presumably transformed into the
sodium salt of some open chain keto-enolic forms (Fig. 5).
These are in turn transformed by treatment with 1 M HCl to
reach a pH value between 8 and 9.6 into reactive inter-
mediates which are entering subsequent condensation pro-
cesses in the weak basic pH range with generation of the
highly active MCS factors. The very low UV absorbance of
the MCS factors in the 200–215 nm range excludes the
formation of aromatic condensation products even as reac-
tion intermediates. By a too rapid admixture of the acid
sometimes an amorphous inactive gel of inorganic nature
(inert to concentrated sulfuric acid) is formed. The scheme
in Fig. 5 summarizes the steps assumed for the activation
procedure.
Small but significant differences in the inhibition poten-
cies of the resulting highly active MCS factors were
observed (Fig. 6) when the probe was kept upon activation
with excess sodium ions (e.g. MCS-402) or when these
were removed with an ion exchanger resin. While a
‘‘sodium-free’’ preparation (e.g. MCS-L04) is capable of
inhibiting the enzyme quantitatively, the MCS-402 prepara-
tion inactivates only 86% of the enzyme even at concen-
trations above 1 AM. Whether the remaining 14% enzymatic
activity in the case of MCS-402 was produced by a slow
turnover of (all) pumps or by an ‘‘inert’’ subpopulation of
the Na,K-ATPase that could not be assessed so far.
Inhibition of rabbit Na,K-ATPase by the two MCS
probes (MCS-L04, MCS-402) is compared in Fig. 6 to the
inhibitory potency of ouabain. The concentration-dependent
inhibition of the enzyme activity, EA, was fitted by the Hill
function EA(c) =EA(0)/(1+(KI/c)
 nH), where EA(0) = 1 (nor-
malized to the specific activity of the uninhibited enzyme),
KI is the inhibitory constant, corresponding to the half-
inhibitory concentration of the compound added, and nH is
Fig. 4. ESI mass spectrum of the MCS-L04 factor in the negative ion mode.
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the Hill coefficient. The inhibitory potencies of MCS-L04
(KI = 38 nM) and MCS-402 (KI = 24 nM) are about 26 or 40
times higher than that of ouabain (KI = 1 AM). While the
concentration-dependency of the MCS preparations could
be fitted by a single binding isotherm, i.e. nH= 1F 0.05, in
the case of ouabain, a higher value of nH, i.e. 1.3, fitted best.
This aspect will be the subject of further investigations
focused on the inhibition mechanism (paper in preparation).
3.4. Inhibition of Na,K-ATPases from different tissues with
MCS factors
It is well known that different isozymes of the Na,K-
ATPase exhibit different affinities for ouabain [3]. A stand-
ard preparation of lower binding affinity for cardiac glyco-
sides can be isolated from rat kidney [19]. The inhibition
potencies of various MCS preparations were determined in
parallel with rabbit and rat enzyme. As shown in Fig. 7, with
MCS factors, no significant discrimination between the two
enzymes could be obtained. The normalized specific
enzyme activity was plotted against the concentration of
the MCS factor (MCS-A02) and fitted with a single binding
isotherm. The KI values of 22.5 nM (rabbit) and 22.3 nM
(rat) correspond to a ratio of KI (rat)/KI (rabbit) = 1. When
fitted with a Hill function, the Hill coefficient with this MCS
preparation was in the order of 1.3 (rat) to 1.8 (rabbit). In the
case of another MCS preparation (MCS-A02), the ratio of
KI (rat)/KI (rabbit) was 1.6 (data not shown). This would
indicate that MCS preparations do not exhibit significant
isozyme specificity, while the KI (rat)/KI (rabbit) determined
in parallel for the same Na,K-ATPase enzyme preparations
with ouabain was f 20 (data not shown). On the other
hand, the various MCS preparations were found to differ in
the Hill coefficient to some extent.
Fig. 6. Concentration dependent inhibition of Na,K-ATPase from rabbit
kidney by differently activated MCS factors: Na+ containing (MCS-402)
and Na+ free (MCS-L04) in comparison with ouabain. The concentration
axis refers to the total inhibitor concentration.
Fig. 7. Comparison of the inhibitory activity of the MCS-A02 factor on
Na,K-ATPase isolated from rabbit and rat kidney.
Fig. 5. Scheme for the preparation of the active MCS factors through the base/acid treatment of the lipophilic precursor form and the presumed intermediates.
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3.5. Inhibition of SR Ca-ATPase with MCS factors
Inhibition of SR Ca-ATPase with the MCS-A02 factor is
shown in Fig. 8. The KI of 31.3 nM was in the same order as
that obtained with Na,K-ATPase. However, when fitted with
a Hill function, the Hill coefficient, nH = 2.56, was signifi-
cantly higher than in the case of the Na,K-ATPases. This
indicates that a different inhibitory mechanism may occur.
Bindings of inhibitors may induce conformational
changes of the whole enzyme or of protein domains as
recently assumed for some lipophilic, hydroxy-containing
inhibitors of the SR Ca-ATPase [28]. Common structural
elements of these molecules (ellagic acid, curcumin, dieth-
ylstilbestrol, etc.) are two or more phenolic hydroxy groups
located on opposed parts of their structural frame.
Plant-derived poly-phenolic and flavonoid compounds
and their synthetic analogs were identified as inhibitors of
plasma membrane Ca-ATPase [29]. A similar polyphenolic
structure is proper to hypericin, the protein kinase inhibitory
substance from St.-John’s-wort, recently identified as potent
inhibitor of Ca-ATPase in lymphoid cells, too [30].
The Ca-ATPase inhibitory potency of the investigated
polyphenolic compounds is with the exception of two
synthetic eosin derivatives in the range of 10–1000 AM
range [29], which is significantly lower than the inhibitory
potency of the MCS factors.
4. Conclusions
Structurally, the new class of natural compounds isolated
from Helleborus purp. are cyclo-oligomers of the inorganic
carbon suboxide with a high tendency to self-association as
well observed in the HPLC behavior. The MCS cyclo-
hexamer, (C3O2)6, with a molar mass of 408.2 Da was
found to be the predominant component with about 2/3 of
the contents, whereas the cyclooctamer (C3O2)8 is present in
lower amounts. Moreover, as evidenced by the ESI-MS
spectra, the MCS factors show a tendency to form com-
plexes with sodium and other ions.
The experimental data show that the MCS factors are
potent and species-independent inhibitors of the Na,K-
ATPase and are also capable of inhibiting the SR Ca-
ATPase. Since the kinetics were always of the type of a
binding isotherm with a well-defined half-saturating con-
centration, interactions with some specific sites of the
protein have to be assumed. In contrast to cardiac glyco-
sides, the MCSs do not discriminate significantly between
rabbit and rat enzyme. This observation may possibly be
explained by different mechanisms of interaction. The MCS
inhibitors may interact with multiple structural elements of
the protein including the ouabain binding site, but in a way
which is not affected by the different amino acid composi-
tions of rabbit and rat enzyme. To gain further insight into
the mode of binding, functional analyses are in progress.
The still open question of the chemical nature of the
endogenous inhibitor(s) of the Na,K-ATPase may possibly
be tackled by the biochemical properties of the MCS
inhibitors which share a high degree of similarity with
EDLFs in their analytical properties. Variations in the
inhibitory activity, as observed here for the MCS deriva-
tives, have often been noticed for EDLF probes [12] and this
observation suggests the existence of a structural equili-
brium between variously active forms. Since MCS factors
are also found in other plants and in bacteria (unpublished
results), the investigation of their physiological activation
and of their inhibitory mechanism may possibly answer the
crucial question whether this class of compounds partici-
pates in the regulation of the Na,K-ATPase and possibly of
other types of ATPases, too.
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